Théroux 1988.

Study characteristics
Methods	Prospective, randomized, double‐blind study
Participants	479 patients with unstable angina (admitted or while hospitalized), within 24 hours preceding the time of randomization
Interventions	4 treatment groups (6 days of therapy), Group 1: ASA 650 mg, then 325 mg bid + UFH placebo (n = 121) Group 2: UFH 5000 U, then 1000 U/hour + placebo ASA Group 3: ASA 650 mg, then 325 mg bid + UFH 5000 U IV, then 1000 U/hour (n = 122) Group 4: placebo + placebo UFH
Outcomes	Primary outcome (6 days and 3 months): refractory angina, MI, death, serious (major) bleeding
Notes	Study was discontinued prematurely on the basis of first interim data analysis. Use only data from Groups 1 and 3
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomization done in blocks
Allocation concealment (selection bias)	Low risk	Pharmacy‐controlled randomization (central)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding probably ensured. Quote: “trial medication prepackaged and coded by the pharmacists on a randomized, double‐blind basis”
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Some key study personnel probably not blinded, but, outcome measurement are not likely to be influenced by the lack of blinding of outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data
Selective reporting (reporting bias)	Low risk	No protocol available, all expected outcomes reported.
Other bias	High risk	The study was discontinued prematurely on the basis of the policy board recommendation after the first interim data analysis

aPTT ‐ activated partial thromboplastin time
ASA ‐ aspirin
CAD ‐ coronary artery disease
INR ‐ international normalized ratio
IV ‐ intravenous
MI ‐ myocardial infarction
NSTEMI ‐ non‐ST segment myocardial infarction
SC ‐ subcutaneous
UFH ‐ unfractionated heparin